Griffith's Institute for Glycomics has partnered with China Grand Pharma’s new Australian company Grand Medical Ltd to develop a drug to treat millions of people with respiratory illnesses.
Griffith’s Institute for Glycomics have made a promising discovery in the treatment and prevention of human parainfluenza virus.
Pre-clinical trials are being planned on a treatment for human parainfluenza virus discovered by the Institute for Glycomics. This treatment could be the first on the market to treat the virus, which causes lower respiratory infections, such as bronchiolitis, pneumonia or croup. A team at the Institute lead by Director Mark von Itzstein has for […]
Researchers at Griffith University’s Institute for Glycomics have moved a step closer to identifying a treatment for the dreaded Human parainfluenza virus (hPIV).